<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A total of 171 patients of young, middle, and old age presenting initial manifestations of cerebral circulatory insufficiency and early disordered-circulatory <z:hpo ids='HP_0001298'>encephalopathy</z:hpo> were treated with cavinton </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical effect of the drug mostly expressed in a considerable decrease of subjective manifestations of the disease was fairly high in most patients of different age groups </plain></SENT>
<SENT sid="2" pm="."><plain>The most pronounced positive shifts (according to REG) of the cerebral hemodynamics upon cavinton therapy were observed in young and middle-aged patients </plain></SENT>
<SENT sid="3" pm="."><plain>A lower efficacy in elderly patients was explained by the fact that there were grave organic changes in the cerebral vessels, predominantly in those of small and medium caliber </plain></SENT>
<SENT sid="4" pm="."><plain>A comprehensive nature of the drug action, as well as the absence of any adverse effect on the cerebral hemodynamics recommend cavinton as a drug of choice in the treatment of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> forms of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, including elderly ones </plain></SENT>
<SENT sid="5" pm="."><plain>The drug should not be administered to patients over 60 years of age with marked disorders of cardiac activity </plain></SENT>
</text></document>